• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

从 COVID-19 到癌症 mRNA 疫苗：疫苗领域从实验室走向临床。

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

机构信息

Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, India.

Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, Gangwon-do, South Korea.

出版信息

Front Immunol. 2021 Jul 7;12:679344. doi: 10.3389/fimmu.2021.679344. eCollection 2021.

DOI:10.3389/fimmu.2021.679344
PMID:34305909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8293291/
Abstract

Recently, mRNA vaccines have become a significant type of therapeutic and have created new fields in the biopharmaceutical industry. mRNA vaccines are promising next-generation vaccines that have introduced a new age in vaccinology. The recent approval of two COVID-19 mRNA vaccines (mRNA-1273 and BNT162b2) has accelerated mRNA vaccine technology and boosted the pharmaceutical and biotechnology industry. These mRNA vaccines will help to tackle COVID-19 pandemic through immunization, offering considerable hope for future mRNA vaccines. Human trials with data both from mRNA cancer vaccines and mRNA infectious disease vaccines have provided encouraging results, inspiring the pharmaceutical and biotechnology industries to focus on this area of research. In this article, we discuss current mRNA vaccines broadly in two parts. In the first part, mRNA vaccines in general and COVID-19 mRNA vaccines are discussed. We presented the mRNA vaccine structure in general, the different delivery systems, the immune response, and the recent clinical trials for mRNA vaccines (both for cancer mRNA vaccines and different infectious diseases mRNA vaccines). In the second part, different COVID-19 mRNA vaccines are explained. Finally, we illustrated a snapshot of the different leading mRNA vaccine developers, challenges, and future prospects of mRNA vaccines.

摘要

最近，mRNA 疫苗已成为一种重要的治疗方法，并在生物制药行业开辟了新的领域。mRNA 疫苗是有前途的下一代疫苗，它开创了疫苗学的新时代。最近两种 COVID-19 mRNA 疫苗（mRNA-1273 和 BNT162b2）的批准加速了 mRNA 疫苗技术的发展，并推动了制药和生物技术行业的发展。这些 mRNA 疫苗将通过免疫接种帮助应对 COVID-19 大流行，为未来的 mRNA 疫苗提供了巨大的希望。来自 mRNA 癌症疫苗和 mRNA 传染病疫苗的临床试验数据提供了令人鼓舞的结果，这激发了制药和生物技术行业专注于这一研究领域。在本文中，我们广泛地将当前的 mRNA 疫苗分为两部分进行讨论。在第一部分中，我们讨论了一般的 mRNA 疫苗和 COVID-19 mRNA 疫苗。我们介绍了 mRNA 疫苗的一般结构、不同的传递系统、免疫反应以及最近的 mRNA 疫苗临床试验（包括癌症 mRNA 疫苗和不同传染病的 mRNA 疫苗）。在第二部分，我们解释了不同的 COVID-19 mRNA 疫苗。最后，我们说明了不同领先的 mRNA 疫苗开发商的概况、挑战和 mRNA 疫苗的未来前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/c849890b94e7/fimmu-12-679344-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/52e0931c1d41/fimmu-12-679344-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/2e810c0fbb3e/fimmu-12-679344-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/6c4bab829351/fimmu-12-679344-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/35b20496561b/fimmu-12-679344-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/f19dd4ee1dab/fimmu-12-679344-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/c849890b94e7/fimmu-12-679344-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/52e0931c1d41/fimmu-12-679344-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/2e810c0fbb3e/fimmu-12-679344-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/6c4bab829351/fimmu-12-679344-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/35b20496561b/fimmu-12-679344-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/f19dd4ee1dab/fimmu-12-679344-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6f8/8293291/c849890b94e7/fimmu-12-679344-g006.jpg

相似文献

1
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.从 COVID-19 到癌症 mRNA 疫苗：疫苗领域从实验室走向临床。
Front Immunol. 2021 Jul 7;12:679344. doi: 10.3389/fimmu.2021.679344. eCollection 2021.
2
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
3
COVID-19 mRNA vaccines.COVID-19 mRNA 疫苗。
J Genet Genomics. 2021 Feb 20;48(2):107-114. doi: 10.1016/j.jgg.2021.02.006. Epub 2021 Mar 15.
4
mRNA vaccines: a new era in vaccine development.mRNA 疫苗：疫苗开发的新时代。
Oncol Res. 2024 Sep 18;32(10):1543-1564. doi: 10.32604/or.2024.043987. eCollection 2024.
5
mRNA vaccine for cancer immunotherapy.用于癌症免疫治疗的信使核糖核酸疫苗
Mol Cancer. 2021 Feb 25;20(1):41. doi: 10.1186/s12943-021-01335-5.
6
Cancer mRNA vaccines: clinical advances and future opportunities.癌症 mRNA 疫苗：临床进展和未来机遇。
Nat Rev Clin Oncol. 2024 Jul;21(7):489-500. doi: 10.1038/s41571-024-00902-1. Epub 2024 May 17.
7
Perspectives and Prospects on mRNA Vaccine Development for COVID-19.mRNA 疫苗开发用于 COVID-19 的观点和展望。
Curr Med Chem. 2022;29(23):3991-3996. doi: 10.2174/0929867329666220216110931.
8
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
9
Messenger RNA vaccines against SARS-CoV-2.针对 SARS-CoV-2 的信使 RNA 疫苗。
Cell. 2021 Mar 18;184(6):1401. doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.
10
Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.开发用于传染病和致癌病毒的 mRNA 疫苗的前景与挑战。
Med Sci (Basel). 2024 May 22;12(2):28. doi: 10.3390/medsci12020028.

引用本文的文献

1
Bevacizumab alternating chemotherapy for improving the survival of patients with recurrent high-grade glioma.贝伐单抗交替化疗用于改善复发性高级别胶质瘤患者的生存期。
Neurooncol Adv. 2025 Jul 18;7(1):vdaf157. doi: 10.1093/noajnl/vdaf157. eCollection 2025 Jan-Dec.
2
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies.伊马替尼治疗的慢性髓性白血病患者使用p210肽进行治疗性疫苗接种：GIMEMA CML0206和SI0207研究的10年随访
Vaccines (Basel). 2025 Apr 16;13(4):419. doi: 10.3390/vaccines13040419.
3
Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.

本文引用的文献

1
Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.综述：接种 COVID-19 mRNA 疫苗的免疫后果：初步结果。
Front Immunol. 2021 Mar 12;12:657711. doi: 10.3389/fimmu.2021.657711. eCollection 2021.
2
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗后的抗体反应。
N Engl J Med. 2021 May 20;384(20):1959-1961. doi: 10.1056/NEJMc2102051. Epub 2021 Mar 23.
3
COVID-19 vaccines: modes of immune activation and future challenges.
超越新冠病毒的起源：新冠疫苗研发五年历程中的重要战略层面
Mol Ther Nucleic Acids. 2025 Mar 28;36(2):102527. doi: 10.1016/j.omtn.2025.102527. eCollection 2025 Jun 10.
4
Making Universal Vaccines and Antibodies Through Glycoengineering.通过糖基工程制备通用疫苗和抗体。
Methods Mol Biol. 2025;2926:35-50. doi: 10.1007/978-1-0716-4542-0_3.
5
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy.信使核糖核酸疫苗平台：连接传染病预防与癌症免疫治疗
Front Bioeng Biotechnol. 2025 Mar 12;13:1547025. doi: 10.3389/fbioe.2025.1547025. eCollection 2025.
6
Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy.用于癌症免疫治疗的mRNA疫苗设计中的计算生物学与人工智能
Front Cell Infect Microbiol. 2025 Jan 20;14:1501010. doi: 10.3389/fcimb.2024.1501010. eCollection 2024.
7
Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions.针对RNA病毒的疫苗策略：当前进展与未来方向
Vaccines (Basel). 2024 Nov 28;12(12):1345. doi: 10.3390/vaccines12121345.
8
Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.多形性胶质母细胞瘤 (GBM) 治疗的实用免疫调节全景。
J Egypt Natl Canc Inst. 2024 Oct 28;36(1):33. doi: 10.1186/s43046-024-00240-4.
9
mRNA vaccine development and applications: A special focus on tumors (Review).mRNA 疫苗的开发与应用：特别关注肿瘤（综述）。
Int J Oncol. 2024 Aug;65(2). doi: 10.3892/ijo.2024.5669. Epub 2024 Jul 12.
10
Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.开发用于传染病和致癌病毒的 mRNA 疫苗的前景与挑战。
Med Sci (Basel). 2024 May 22;12(2):28. doi: 10.3390/medsci12020028.
COVID-19 疫苗：免疫激活模式和未来挑战。
Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x.
4
mRNA Vaccines for COVID-19: A Simple Explanation.用于新冠肺炎的信使核糖核酸疫苗：简单解释
Qatar Med J. 2021 Feb 18;2021(1):07. doi: 10.5339/qmj.2021.07. eCollection 2021.
5
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
6
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.2020年12月14日至2021年1月18日美国接种mRNA新冠疫苗后发生过敏反应的报告
JAMA. 2021 Mar 16;325(11):1101-1102. doi: 10.1001/jama.2021.1967.
7
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日：在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
8
Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.SARS-CoV-2 候选疫苗：III 期临床试验的预期和疫苗批准后的建议。
Viruses. 2020 Dec 31;13(1):54. doi: 10.3390/v13010054.
9
Latest updates on COVID-19 vaccines.关于 COVID-19 疫苗的最新消息。
Biosci Trends. 2021 Jan 23;14(6):463-466. doi: 10.5582/bst.2020.03445. Epub 2020 Dec 25.
10
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.